MFOLFOXIRI Plus PD-1 Inhibitor Vs MFOLFOX6 As Neoadjuvant Therapy for Locally Advanced Colon Cancer

Inclusion Criteria

• •1. Willing and able to provide written informed consent.
• •2. Histological or cytological documentation of adenocarcinoma of the colon (≥ 12 cm from the anal verge).
• •3. Determined preoperatively by either spiral or multidetector CT: T4 or N2.
• •4. Male or female subjects \> 18 years \< 70 of age.
• •5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• •6. CT or MRI scans (done within 30 days of registration) of the chest, abdomen and pelvis all without clear evidence of distant metastatic (M1) disease.
• •7. No clinically significant obstruction, perforation, or bleeding related to the primary tumor.
• •8. No previous any systemic anticancer therapy for colon cancer disease.
• •9. Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment